Seres Therapeutics, Inc. (MCRB)
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
$160.00M
Mr. Eric D. Shaff M.B.A.
333.00
Cambridge, MA
Jun 26, 2015
-0.88
$-1.19
0.66
1.38
-43,343.58%
-1.03
-0.04
-1.91
448.18
0.89
-50.39%
313.56%
Similar stocks (4)
Iovance Biotherapeutics, Inc.
IOVA
Veracyte, Inc.
VCYT
Fate Therapeutics, Inc.
FATE
Syros Pharmaceuticals, Inc.
SYRS
ETF Exposure (14)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.495%
Schwab U.S. Small-Cap ETF
SCHA
0.0021596416%
Schwab U.S. Broad Market ETF
SCHB
1.437291e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Health Care Index Fund
VHT
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (4)
Iovance Biotherapeutics, Inc.
IOVA
Veracyte, Inc.
VCYT
Fate Therapeutics, Inc.
FATE
Syros Pharmaceuticals, Inc.
SYRS
ETF Exposure (14)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.495%
Schwab U.S. Small-Cap ETF
SCHA
0.0021596416%
Schwab U.S. Broad Market ETF
SCHB
1.437291e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Health Care Index Fund
VHT
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%